Valuation: KDventures AB

Capitalization 20Cr 2.14Cr 1.84Cr 1.69Cr 1.59Cr 2.94Cr 206.76Cr 3.01Cr 7.83Cr 97Cr 8.01Cr 7.84Cr 339.88Cr P/E ratio 2024
-31.7x
P/E ratio 2025 -0.61x
Enterprise value 18Cr 1.89Cr 1.63Cr 1.5Cr 1.41Cr 2.61Cr 183.32Cr 2.67Cr 6.94Cr 86Cr 7.11Cr 6.95Cr 301.35Cr EV / Sales 2024
118x
EV / Sales 2025 56.8x
Free-Float
50.01%
Yield 2024 *
-
Yield 2025 -
1 day+2.30%
1 week+9.15%
Current month+18.55%
1 month+19.92%
3 months+4.20%
6 months-62.38%
Current year-28.90%
1 week 0.28
Extreme 0.2815
0.33
1 month 0.25
Extreme 0.2465
0.33
Current year 0.2
Extreme 0.2
0.45
1 year 0.2
Extreme 0.2
1.34
3 years 0.2
Extreme 0.2
1.95
5 years 0.2
Extreme 0.2
11.24
10 years 0.2
Extreme 0.2
11.24
Manager TitleAgeSince
Chief Executive Officer 61 01/06/2017
Director of Finance/CFO 58 01/10/2022
Chief Investment Officer - -
Director TitleAgeSince
Director/Board Member 33 28/11/2017
Director/Board Member 57 19/02/2021
Chairman 50 18/12/2024
Change 5d. change 1-year change 3-years change Capi.($)
+1.64%+9.15%-68.59%-81.10% 2.14Cr
+1.04%+5.30%-34.47%-18.46% 15TCr
+1.63%+2.29%-9.65%-12.03% 10TCr
-1.47%-4.26%+48.54%+63.08% 5.65TCr
+1.64%+2.01%-9.04%+53.51% 5.18TCr
+3.23%-0.38%-17.00%-41.66% 4.05TCr
+4.66%-2.20% - - 3.19TCr
+2.86%+9.50%-23.01%-42.84% 2.58TCr
-0.16%-2.61%+39.92%-13.51% 2.15TCr
+2.11%+20.13%-13.05%+10.52% 2.13TCr
Average +1.37%+3.23%-9.59%-9.17% 5.05TCr
Weighted average by Cap. +0.88%+3.03%-10.01%-1.26%

Financials

2024 2025
Net sales 18.38L 2L 2L 2L 1L 3L 1.89Cr 3L 7L 88.97L 7L 7L 3.11Cr 16.71L 2L 2L 1L 1L 2L 1.72Cr 3L 7L 80.89L 7L 7L 2.82Cr
Net income -81.01L -9L -7L -7L -6L -11.84L -8.33Cr -12.14L -31.55L -3.92Cr -32.29L -31.6L -14Cr -19Cr -2.06Cr -1.78Cr -1.63Cr -1.54Cr -2.83Cr -199.33Cr -2.91Cr -7.55Cr -94Cr -7.73Cr -7.56Cr -327.67Cr
Net Debt -3.99Cr -42.37L -36.55L -33.48L -31.64L -58.32L -41Cr -59.79L -1.55Cr -19Cr -1.59Cr -1.56Cr -67Cr -2.28Cr -24.21L -20.88L -19.13L -18.08L -33.32L -23Cr -34.16L -88.77L -11Cr -90.85L -88.92L -39Cr
Logo KDventures AB
Karolinska Development AB is a Sweden-based investment company. The Company provides capital to biotechnology firms, as well as develops and commercializes biotechnological products. Its activities are involved in a range of areas: oncology, infections and wound healing, women’s health, cardiovascular and hematology, medical equipment, diagnostics, pharmaceutical formulation, as well as implants, among others. The Company’s pharmaceuticals portfolio comprises: AXL1717 for non-small-cell lung carcinoma (NSCLC), APR-246 for ovarian cancer, Sevuparin for malaria, SHACT for pain relief at hysteroscopy and intrauterine device (IUD) insertion, and PC-mAB for acute coronary syndrome (ACS), among others. Furthermore, the Company controls a number of subsidiaries, such as Avaris AB, HBV Thernostica AB, KD Incentive AB, KDev Oncology AB and Limone AB.
Employees
7
Date Price Change Volume
20/26/20 0.3100 kr +1.64% 13,90,150
19/26/19 0.3050 kr +1.67% 8,60,160
18/26/18 0.3000 kr +0.17% 31,14,896
15/26/15 0.2995 kr +5.46% 17,79,467
13/26/13 0.2840 kr -3.73% 11,16,477

Annual profits - Rate of surprise